The IRGPI-high group has high expression of CTLA-4 and a small number of CD8 + T cells in the tumor microenvironment, which may be an indication for a combination of anti-PD-1/PD-L1 and anti-CTLA-4. The gene discussed is CTLA4; the disease is neoplasm.